↓ Skip to main content

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Overview of attention for book
Attention for Chapter 8: Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Chapter number 8
Book title
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Published in
Advances in experimental medicine and biology, December 2015
DOI 10.1007/978-3-319-24932-2_8
Pubmed ID
Book ISBNs
978-3-31-924931-5, 978-3-31-924932-2
Authors

Hussain, Sajid, Sajid Hussain Ph.D., Sajid Hussain

Editors

Aamir Ahmad, Shirish M. Gadgeel

Abstract

Lung cancer is the second most common cancer and the primary cause of cancer-related death in both men and women in the United States and rest of the world. Due to diagnosis at an advanced stage, it is associated with a high mortality in a majority of patients. In recent years, enormous advances have occurred in the development and application of nanotechnology in the detection, diagnosis, and therapy of cancer. This progress has led to the development of the emerging field of "cancer nanomedicine." Nanoparticle-based therapeutic systems have gained immense popularity due to their bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. Currently, a plethora of nanocarrier formulations are utilized including lipid-based, polymeric and branched polymeric, metal-based, magnetic, and mesoporous silica. In lung cancer, nanoparticle-based therapeutics is paving the way in the diagnosis, imaging, screening, and treatment of primary and metastatic tumors. The application and expansion of novel nanocarriers for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies. Some of the current progress and challenges in nanoparticle-based drug delivery systems for lung cancer treatment are discussed.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Brazil 1 2%
Unknown 39 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 32%
Student > Master 5 12%
Student > Ph. D. Student 4 10%
Professor > Associate Professor 4 10%
Other 2 5%
Other 7 17%
Unknown 6 15%
Readers by discipline Count As %
Medicine and Dentistry 8 20%
Pharmacology, Toxicology and Pharmaceutical Science 8 20%
Engineering 4 10%
Biochemistry, Genetics and Molecular Biology 4 10%
Social Sciences 2 5%
Other 6 15%
Unknown 9 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2016.
All research outputs
#9,408,538
of 11,770,557 outputs
Outputs from Advances in experimental medicine and biology
#1,785
of 3,122 outputs
Outputs of similar age
#193,976
of 275,987 outputs
Outputs of similar age from Advances in experimental medicine and biology
#13
of 23 outputs
Altmetric has tracked 11,770,557 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,122 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,987 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.